Vertex Pharmaceuticals
NEWS
The company is eager to diversify, putting Phase II clinical trials in sickle-cell disease, beta-thalassemia, kidney diseases, and pain management.
Yao has more than 15 years of experience in the cell and gene therapy fields. He also established and directed the Cell Therapy R&D business unit, with a focus on CAR-T development.
The data showed that both experimental therapies restored function in the cystic fibrosis transmembrane conductance regulator gene.
Shares of Vertex fell more than 13% in premarket trading after it announced that it will not advance a novel small molecule corrector of the Z-AAT protein into a Phase III study.
June is turning out to be a busy month for PDUFA dates for the U.S. Food and Drug Administration. Here’s a look at this week’s dates.
“The recent progress of cystic fibrosis drugs has been amazing and, in my case, miraculous,” said Kelly Peters, who lives with cystic fibrosis. “The new drugs are not a cure, but they feel pretty close.”
BioSpace takes an in-depth look at the Top 25 of Q1. You should be aware of these biopharma companies as they hold a great future ahead. So, check them out.
Executives at pharmaceutical companies are known for receiving large salaries. When bonuses and stock options are factored into the picture, their annual compensation can jump into the range of tens of millions of dollars, like Pfizer’s Albert Bourla, Alex Gorsky from Johnson & Johnson, and AstraZeneca’s Pascal Soriot.
Under the terms of the expanded deal, Vertex will be responsible for 60% of the costs of developing, manufacturing and commercializing CTX001 with support from CRISPR Therapeutics, and will receive 60% of profits from global sales.
JOBS
IN THE PRESS